A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.

NCT Number	NCT07690826
Lead Sponsor	Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions	Overweight or Obesity
Enrollment	252 participants
Start Date	2026-07
Primary Completion	2027-03 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-08